PA8799901A1 - Derivado de triazol 1,3,5-trisustituido - Google Patents

Derivado de triazol 1,3,5-trisustituido

Info

Publication number
PA8799901A1
PA8799901A1 PA20088799901A PA8799901A PA8799901A1 PA 8799901 A1 PA8799901 A1 PA 8799901A1 PA 20088799901 A PA20088799901 A PA 20088799901A PA 8799901 A PA8799901 A PA 8799901A PA 8799901 A1 PA8799901 A1 PA 8799901A1
Authority
PA
Panama
Prior art keywords
trisustituted
triazol
invention refers
triazol derivative
derivative
Prior art date
Application number
PA20088799901A
Other languages
English (en)
Inventor
Johannes Wilhelmus John F Thuring
Theodorus Dinklo
Anne Simone Josephine Lesage
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of PA8799901A1 publication Critical patent/PA8799901A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

ESTA INVENCIÒN SE REFIERE A 2-(2,6-DIMETIL-PIRIDIN-4-IL)-[1,2,4]TRIAZOL-1-IL]-N-ETIL-ACETAMIDA Y ANÀLOGOS O SUS SALES ACEPTABLES PARA USO FARMACÈUTICO A PROCESOS PARA PREPARARLOS, A COMPOSICIONES FARMACÈUTICAS QUE LOS CONTIENEN Y A SU USO EN TERAPIA. LA INVENCIÒN SE REFIERE EN PARTICULAR A UN MODULADOR ALOSTÈRICO POSITIVO POTENTE DE LOS RECEPTORES NICOTINICOS DE LA ACETICOLINA QUE TIENEN LA CAPACIDAD DE AUMENTAR LA EFICACIA DE LOS AGONISTAS DE LOS RECEPTORES NICOTÌNICOS.
PA20088799901A 2007-10-18 2008-10-17 Derivado de triazol 1,3,5-trisustituido PA8799901A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07118822 2007-10-18

Publications (1)

Publication Number Publication Date
PA8799901A1 true PA8799901A1 (es) 2009-05-15

Family

ID=39047591

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20088799901A PA8799901A1 (es) 2007-10-18 2008-10-17 Derivado de triazol 1,3,5-trisustituido

Country Status (18)

Country Link
US (1) US8404851B2 (es)
EP (1) EP2205594B1 (es)
JP (1) JP2011500624A (es)
CN (1) CN101827839B (es)
AR (1) AR068919A1 (es)
AT (1) ATE522523T1 (es)
AU (1) AU2008313775B2 (es)
CA (1) CA2697982C (es)
CL (1) CL2008003067A1 (es)
ES (1) ES2371863T3 (es)
IL (1) IL205102A (es)
JO (1) JO2784B1 (es)
MX (1) MX2010004176A (es)
PA (1) PA8799901A1 (es)
PE (1) PE20091080A1 (es)
RU (1) RU2476433C2 (es)
TW (1) TW200934491A (es)
WO (1) WO2009050185A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ576570A (en) * 2006-10-19 2010-11-26 Takeda Pharmaceutical 7-sulfonylamino-2-thiazol and 2-thiadiazol -indole compounds
CA2697974C (en) * 2007-10-18 2015-06-30 Janssen Pharmaceutica Nv Trisubstituted 1,2,4-triazoles
KR101564303B1 (ko) * 2008-03-19 2015-11-06 얀센 파마슈티카 엔.브이. 니코틴성 아세틸콜린 수용체 조절제로서의 삼치환된 1,2,4-트리아졸
WO2009135944A1 (en) * 2008-05-09 2009-11-12 Janssen Pharmaceutica Nv Trisubstituted pyrazoles as acetylcholine receptor modulators
CN103443092B (zh) 2011-02-03 2015-11-25 鲁平有限公司 用作α7胆碱受体调节剂的吡咯衍生物
CU24177B1 (es) 2011-02-23 2016-04-25 Lupin Ltd Derivados de heteroarilo como moduladores de nachr alfa 7
CA2824350C (en) 2011-02-25 2019-07-02 Janssen Pharmaceutica Nv (pyridin-4-yl)benzylamides as allosteric modulators of alpha 7 nachr
JP2014509641A (ja) 2011-03-31 2014-04-21 ルピン・リミテッド アルツハイマー病やパーキンソン病などの神経変性疾患の治療に用いられるニコチン性アセチルコリン受容体モジュレータとしてのピロール誘導体
WO2013005153A1 (en) 2011-07-05 2013-01-10 Lupin Limited Biaryl derivatives as nachr modulators
EP2822946A1 (en) 2012-03-06 2015-01-14 Lupin Limited Thiazole derivatives as alpha 7 nachr modulators
EP2945936A1 (en) 2012-11-12 2015-11-25 Lupin Limited Thiazole derivatives as alpha 7 nachr modulators
WO2014111839A1 (en) 2013-01-16 2014-07-24 Lupin Limited Pyrrole derivatives as alpha 7 nachr modulators
CA2892682A1 (en) 2013-03-13 2014-09-18 Lupin Limited Pyrrole derivatives as alpha 7 nachr modulators
TW201446243A (zh) 2013-06-03 2014-12-16 Lupin Ltd 4-(5-(4-氯苯基)-2-(2-環丙基乙醯基)-1,4-二甲基-1氫-吡咯-3-基)苯磺醯胺作為α7尼古丁乙醯膽鹼受體調節劑
AU2014282886A1 (en) 2013-06-17 2015-12-17 Lupin Limited Pyrrole derivatives as alpha 7 nAChR modulators

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE795907A (fr) * 1972-02-25 1973-06-18 Luso Farmaco Inst 2-amino-4-arylthiazoles 5-substitues et leur preparation
EP0248523B1 (en) 1986-05-07 1991-10-16 FISONS plc Pyrazoles
JPS6339868A (ja) 1986-08-04 1988-02-20 Otsuka Pharmaceut Factory Inc ジ低級アルキルフエノ−ル誘導体
US4761422A (en) 1986-11-20 1988-08-02 Lusofarmaco Istituto Lusofarmaco D'italia Spa (2-amino-4-aryl-thiazole-5-yl)ethanols and their derivatives having diuretic activity and methods for preparing the same
CA2195847A1 (en) 1994-07-27 1996-02-08 John J. Talley Substituted thiazoles for the treatment of inflammation
KR970705560A (ko) 1995-08-02 1997-10-09 호아껭 우리아치 토렐로 항진균 활성을 갖는 신규한 카르복사미드(new carboxamides with antifungal activity)
FR2754258B1 (fr) 1996-10-08 1998-12-31 Sanofi Sa Derives d'aminothiazole, leur procede de preparation et les compositions pharmaceutiques les contenant
US6187797B1 (en) * 1996-12-23 2001-02-13 Dupont Pharmaceuticals Company Phenyl-isoxazoles as factor XA Inhibitors
WO1998028282A2 (en) 1996-12-23 1998-07-02 Du Pont Pharmaceuticals Company OXYGEN OR SULFUR CONTAINING 5-MEMBERED HETEROAROMATICS AS FACTOR Xa INHIBITORS
EP1027050B1 (en) 1997-10-27 2004-01-14 Takeda Chemical Industries, Ltd. 1,3-thiazoles as adenosine a3 receptor antagonists for the treatment of allergy, asthma and diabetes
FR2792314B1 (fr) * 1999-04-15 2001-06-01 Adir Nouveaux composes aminotriazoles, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
DE60007697T2 (de) * 1999-07-21 2004-12-09 F. Hoffmann-La Roche Ag Triazolderivate
WO2001010865A1 (fr) 1999-08-06 2001-02-15 Takeda Chemical Industries, Ltd. INHIBITEURS DE p38MAP KINASE
FR2802530B1 (fr) 1999-12-17 2002-02-22 Sanofi Synthelabo Nouveaux derives amino substitues ramifies du 3-amino-1-phenyl-1h[1,2,4]triazole, procedes pour leur preparation et compositions pharmaceutiques les contenant
ES2317889T3 (es) 2000-03-01 2009-05-01 Janssen Pharmaceutica Nv Derivados de tiazolilo 2,4-disustituido.
US6586453B2 (en) 2000-04-03 2003-07-01 3-Dimensional Pharmaceuticals, Inc. Substituted thiazoles and the use thereof as inhibitors of plasminogen activator inhibitor-1
HUP0303038A2 (hu) 2000-09-21 2003-12-29 Bristol-Myers Squibb Co. Szubsztituált azolszármazékok mint kortikotropin releasing faktor inhibitorok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
GB0028383D0 (en) 2000-11-21 2001-01-03 Novartis Ag Organic compounds
US6924302B2 (en) 2000-12-22 2005-08-02 Ortho Mcneil Pharmaceutical, Inc. Substituted triazole diamine derivatives as kinase inhibitors
ES2407807T3 (es) 2001-08-13 2013-06-14 Janssen Pharmaceutica N.V. Derivados de tiazolilo 2-amino-4,5-trisustituidos y su uso frente a enfermedades autoinmunitarias
US20050004134A1 (en) * 2001-11-08 2005-01-06 Hideo Tsutsumi Thiazole derivative and pharmaceutical use thereof
EP1467981A1 (en) 2002-01-25 2004-10-20 Kylix Pharmaceuticals B.V. 4(hetero-) aryl substituted (thia-/oxa-/pyra) zoles for inhibition of tie-2
JP3600832B2 (ja) * 2002-01-28 2004-12-15 株式会社富士薬品 新規１，２，４−トリアゾール系化合物
CN1653068A (zh) 2002-05-07 2005-08-10 神经研究公司 新的二氮杂双环联芳基衍生物
EP1532132B1 (en) * 2002-07-29 2008-03-19 F.Hoffmann-La Roche Ag Novel benzodioxoles
AR042052A1 (es) * 2002-11-15 2005-06-08 Vertex Pharma Diaminotriazoles utiles como inhibidores de proteinquinasas
US20070191267A1 (en) 2003-04-28 2007-08-16 Ab Science Use of tyrosine kinase inhibitors for treating cerebral ischemia
US7244739B2 (en) 2003-05-14 2007-07-17 Torreypines Therapeutics, Inc. Compounds and uses thereof in modulating amyloid beta
CA2528438A1 (en) * 2003-06-03 2005-01-06 Novartis Ag P-38 inhibitors
EP1648876A1 (en) 2003-07-24 2006-04-26 Pharmagene Laboratories Ltd 5-ht sb 2b /sb receptor antagonists
FR2862647B1 (fr) 2003-11-25 2008-07-04 Aventis Pharma Sa Derives de pyrazolyle, procede de preparation et intermediaires de ce procede a titre de medicaments et de compositions pharmaceutiques les renfermant
GB0401336D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
CN1942450A (zh) * 2004-02-11 2007-04-04 詹森药业有限公司 取代三唑化合物的制备方法
ZA200702645B (en) * 2004-09-17 2008-08-27 Vertex Pharma Diaminotriazole compounds useful as protein kinase inhibitors
BRPI0517435A (pt) 2004-10-21 2008-10-07 Vertex Pharma triazóis úteis como inibidores de proteìna cinase
WO2006064375A2 (en) 2004-12-16 2006-06-22 Ab Science Aminoaryl substituted five-membered ring heterocyclic compounds for the treatment of diseases
MX2007008434A (es) * 2005-01-19 2007-07-25 Squibb Bristol Myers Co Derivados de 2-fenoxi-n-(1,3,4-tiadizol-2il)piridin-3-amina y compuestos relacionados como inhibidores del receptor p2y1 para el tratamiento de trastornos tromboembolicos.
EA015034B1 (ru) * 2005-09-13 2011-04-29 Янссен Фармацевтика Н.В. 2-анилин-4-арилзамещенные тиазольные производные
JO3019B1 (ar) * 2006-04-19 2016-09-05 Janssen Pharmaceutica Nv ثلاثي مستبدل 4،2،1-ثلاثي زولات
CA2697974C (en) * 2007-10-18 2015-06-30 Janssen Pharmaceutica Nv Trisubstituted 1,2,4-triazoles
KR101564303B1 (ko) * 2008-03-19 2015-11-06 얀센 파마슈티카 엔.브이. 니코틴성 아세틸콜린 수용체 조절제로서의 삼치환된 1,2,4-트리아졸
ES2392795T3 (es) 2008-04-17 2012-12-13 Proximagen Limited Indoles como moduladores del receptor nicotínico de acetilcolina de subtipo alfa-7
WO2009135944A1 (en) * 2008-05-09 2009-11-12 Janssen Pharmaceutica Nv Trisubstituted pyrazoles as acetylcholine receptor modulators
CN102574832B (zh) * 2009-09-17 2014-09-24 詹森药业有限公司 取代的n-苯基-1-(4-吡啶基)-1h-吡唑-3-胺
JO3078B1 (ar) * 2009-11-27 2017-03-15 Janssen Pharmaceutica Nv مورفولينوثيازولات بصفتها منظمات الوستيرية نوع الفا 7 موجبة
CA2824350C (en) 2011-02-25 2019-07-02 Janssen Pharmaceutica Nv (pyridin-4-yl)benzylamides as allosteric modulators of alpha 7 nachr

Also Published As

Publication number Publication date
CA2697982A1 (en) 2009-04-23
IL205102A (en) 2015-04-30
IL205102A0 (en) 2010-11-30
CN101827839A (zh) 2010-09-08
AR068919A1 (es) 2009-12-16
PE20091080A1 (es) 2009-08-03
ATE522523T1 (de) 2011-09-15
CA2697982C (en) 2015-09-22
WO2009050185A1 (en) 2009-04-23
TW200934491A (en) 2009-08-16
US20100240707A1 (en) 2010-09-23
RU2476433C2 (ru) 2013-02-27
US8404851B2 (en) 2013-03-26
JO2784B1 (en) 2014-03-15
JP2011500624A (ja) 2011-01-06
MX2010004176A (es) 2010-05-03
EP2205594B1 (en) 2011-08-31
ES2371863T3 (es) 2012-01-10
CN101827839B (zh) 2012-10-24
CL2008003067A1 (es) 2009-11-27
RU2010119458A (ru) 2011-11-27
AU2008313775A1 (en) 2009-04-23
EP2205594A1 (en) 2010-07-14
AU2008313775B2 (en) 2012-12-13

Similar Documents

Publication Publication Date Title
PA8799901A1 (es) Derivado de triazol 1,3,5-trisustituido
CL2018003290A1 (es) Amidas heterocíclicas útiles como moduladores de proteínas (divisional de solicitud cl 2850-2018).
GT200900292A (es) "inhibidores de cinasa p70 s6"
HN2009001145A (es) Compuestos y composiciones como inhibidores de proteina quinasa
CR11333A (es) cis-IMIDAZOLINAS QUIRALES
UY30942A1 (es) Nuevos derivados de 3-([1,2,4,]triazolo[4,3-a]piridin-7-il)benzamida
DOP2011000264A (es) Derivados de aminotetralina, composiciones farmaceuticas que los contienen y sus usos en terapia
ECSP055853A (es) Nuevos derivados de fluoroglicosidos heterociclicos, productos farmaceuticos que contienen dichos compuestos, y el uso de los mismos
CL2008002131A1 (es) Compuestos heterociclos de amidas derivados de pirimidinas sustituidas por heterociclos y heterobiciclicos, inhibidores de la proteincinasa; composicion farmaceutica; y uso de los compuestos en el tratamiento de enfermedades proliferativas, neurologicas o neurodegenerativas, cardiovasculares, virosica o fungicas.
CR10832A (es) Compuestos y composiciones como inhibidores de la proteina quinasa
SV2010003767A (es) Compuestos pirazolicos 436
UY30304A1 (es) Moduladores de mglur5 i
HN2011000874A (es) Inhibidores de las enzimas de proteina cinasa activadas por mitogeno p38
UY31721A1 (es) 1,2,4-triazoles trisustituidos
NI200900170A (es) Derivados de isoindolina 4' - o - sustituidos y composiciones que los comprenden y métodos para usar los mismos.
UY32351A (es) Compuestos de pirimidinil indol para uso como inhibidores de atr
GT200900283A (es) "terapia de combinación con un compuesto actuando como un inhibidor del receptor adp plaquetario".
SV2009003334A (es) Moduladores receptores de niconítico de acetilcolina
UY30308A1 (es) Moduladores de mglur5 v
PA8720801A1 (es) Nuevas combinaciones terapeuticas para el tratamiento de la depresion
CL2008002430A1 (es) Compuestos derivados de bencenosulfonamida, inhibidores de catepsina c; composicion farmaceutica que los comprende; y su uso para el tratamiento de la epoc.
UY30307A1 (es) Moduladores de mglur5 vi
PA8803201A1 (es) Derivados acidos de cicloalquilamino
GT200600366A (es) Compuestos de imidazol sustituido como inhibidores de ksp
UY30306A1 (es) Moduladores de mglur5 iii